FDA Approves New CAR T Cell for Multiple Myeloma FDA Approves New CAR T Cell for Multiple Myeloma

Ciltacabtagene autoleucel  (cilta-cel) is indicated for patients with relapsed/refractory multiple myeloma who have already had many previous treatments.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news